UT-MD Anderson Cancer Center: Novel Immunotherapy Delivery Approach Safe and Beneficial for Some Melanoma Patients With Leptomeningeal Disease
March 31, 2023
March 31, 2023
HOUSTON, Texas, March 31 (TNSjou) -- The University of Texas's MD Anderson Cancer Center issued the following news release on March 30, 2023:
* * *
Concurrent intrathecal and intravenous treatment improves outcomes in subset of patients
* * *
A novel approach to administer intrathecal (IT) immunotherapy (directly into the spinal fluid) and intravenous (IV) immunotherapy was safe and improved survival in a subset of patients with leptomeningeal . . .
* * *
Concurrent intrathecal and intravenous treatment improves outcomes in subset of patients
* * *
A novel approach to administer intrathecal (IT) immunotherapy (directly into the spinal fluid) and intravenous (IV) immunotherapy was safe and improved survival in a subset of patients with leptomeningeal . . .